Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sublingual Fentanyl on Breathlessness in COPD
NCT04004117Phase 3Terminated
- Sponsor
- McGill University Health Centre
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fentanyl (transdermal patch + oral transmucosal lozenge) in chronic obstructive pulmonary disease (COPD), sponsored by McGill University Health Centre. Started Jul 2019; status: terminated.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04004117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004117.